Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.

Chen X, Xu Y, Zhang J, Shao S, Duan Y, Liu P, Shen L, Zhang J, Zeng J, Lin M, Zhao S, Ma J and 13 more

Show all authors

Zhao T, Hu J, Liao Y, Chen X, Hu S, Xue Y, Zeng Z, He W, Liu Z, Li W, Liu L, Yin P, Yu X

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists6 Apr 2021Cited by 5 (Europe PMC)

PMID33831552DOI10.1016/j.eprac.2021.03.015PepBankPUB-33831552

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide plus glargine improved HbA1c more than aspart 70/30.
In plain wordsIn type 2 diabetes, exenatide plus glargine lowered HbA1c more than aspart 70/30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 180
Comparator
Aspart 70/30 twice daily
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c least squares mean change
−0.59%
exenatide plus glargine
HbA1c least squares mean change
−0.13%
aspart 70/30
HbA1c difference
−0.45%
exenatide plus glargine vs aspart 70/30; 95% CI -0.74 to -0.17
Source sentences
Summary
After 24 weeks, the patients receiving exenatide plus glargine (n = 90) had improved HbA1c control compared with those receiving aspart 70/30 (n = 90) (least squares mean change: ‒0.59 vs ‒0.13%; difference [95% CI]: ‒0.45 [‒0.74 to ‒0.17]) in the full analysis set population.
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155201
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide plus glargine reduced weight more than aspart 70/30.
In plain wordsIn type 2 diabetes, exenatide plus glargine reduced weight more than aspart 70/30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight
Study
n = 180
Comparator
Aspart 70/30 twice daily
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−3.5 kg
exenatide plus glargine
Weight change
−0.4 kg
aspart 70/30
Source sentences
Summary
Weight decreased 3.5 kg with exenatide and decreased 0.4 kg with aspart 70/30 (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155202
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, insulin dose decreased with exenatide plus glargine but increased with aspart 70/30.
In plain wordsIn type 2 diabetes, insulin dose fell with exenatide plus glargine but rose with aspart 70/30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin dose
Study
n = 180
Comparator
Aspart 70/30 twice daily
Outcome group
Patterns of use · Metabolic and weight
Measurements
Insulin dose change
−10.7 units/day
exenatide plus glargine
Insulin dose change
9.7 units/day
aspart 70/30
Source sentences
Summary
The insulin dose was reduced 10.7 units/day (95% CI, ‒12.2 to ‒9.2 units; P < .001) with exenatide, and increased 9.7 units/day (95% CI, 8.2 to 11.2 units; P < .001) with aspart 70/30.
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155203
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In type 2 diabetes, hypoglycemia incidence was similar with exenatide plus glargine and aspart 70/30.
In plain wordsIn type 2 diabetes, low blood sugar occurred at similar rates with exenatide plus glargine and aspart 70/30.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHypoglycemia
Study
n = 180
Comparator
Aspart 70/30 twice daily
Outcome group
Adverse events · Metabolic and weight
Measurements
Hypoglycemia incidence
27%
exenatide plus glargine
Hypoglycemia incidence
38%
aspart 70/30
Source sentences
Summary
The incidence of hypoglycemia was similar in 2 groups (27% for exenatide and 38% for aspart 70/30; P = .1).
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155207
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In type 2 diabetes, nausea occurred in 21% of the exenatide plus glargine group.
In plain wordsIn type 2 diabetes, 21% of patients receiving exenatide plus glargine had nausea.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea incidence
21%
exenatide plus glargine group
Source sentences
Summary
The most common adverse events were gastrointestinal adverse effects in the exenatide group (nausea [21%], vomiting [16%], diarrhea [13%]).
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155204
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In type 2 diabetes, vomiting occurred in 16% of the exenatide plus glargine group.
In plain wordsIn type 2 diabetes, 16% of patients receiving exenatide plus glargine had vomiting.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableVomiting
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Vomiting incidence
16%
exenatide plus glargine group
Source sentences
Summary
The most common adverse events were gastrointestinal adverse effects in the exenatide group (nausea [21%], vomiting [16%], diarrhea [13%]).
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155205
07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In type 2 diabetes, diarrhea occurred in 13% of the exenatide plus glargine group.
In plain wordsIn type 2 diabetes, 13% of patients receiving exenatide plus glargine had diarrhea.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiarrhea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Diarrhea incidence
13%
exenatide plus glargine group
Source sentences
Summary
The most common adverse events were gastrointestinal adverse effects in the exenatide group (nausea [21%], vomiting [16%], diarrhea [13%]).
1 context sentence(design, population, supporting numbers)
Summary · context
After a 12-week premixed human insulin 70/30 dosage optimization period, 200 patients with HbA1c of 7.0% to 10.0% were randomized into 24-week treatment groups with exenatide twice a day plus glargine or with aspart 70/30 twice a day.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3383155206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.